Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Avenue Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +3 vs. Q3 2022
- Shares held
- 448.9K
- +372.9K (+491.2%) vs. Q3 2022
- Total value
- $520.5K
- −$245.5K (−32.1%) vs. Q3 2022
- New holders
- 7
- 5 more added
- Sold out
- 4
- 0 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATXI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 7 | $385.3K |
| Q3 2024 | 8 | $491.8K |
| Q2 2024 | 9 | $407.2K |
| Q1 2024 | 14 | $168.9K |
| Q4 2023 | 15 | $52.4K |
| Q3 2023 | 14 | $157.3K |
| Q2 2023 | 12 | $849.4K |
| Q1 2023 | 14 | $532.7K |
| Q4 2022 | 14 | $520.5K |
| Q3 2022 | 11 | $766.0K |
| Q2 2022 | 19 | $181.0K |
| Q1 2022 | 17 | $503.0K |
| Q4 2021 | 18 | $2.14M |
| Q3 2021 | 21 | $1.62M |
| Q2 2021 | 29 | $2.88M |
| Q1 2021 | 34 | $11.1M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Avenue Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 55 | $0 | 0.00% | +55 | New |
| Bank of America Corp | 12 | $14 | 0.00% | +11+1,100.0% | Added |
| Emfo, LLC | 533 | $618 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,246 | $1.45K | 0.00% | +108+9.5% | Added |
| BlackRock Inc. | 1,941 | $2.25K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 3,332 | $3.87K | 0.00% | +1,858+126.1% | Added |
| Wells Fargo & Company | 4,561 | $5.29K | 0.00% | +23+0.5% | Added |
| Bayesian Capital Management, LP | 11,000 | $12.8K | 0.00% | +11,000 | New |
| Geode Capital Management, LLC | 11,534 | $13.0K | 0.00% | +11,534 | New |
| Citigroup Inc | 17,321 | $20.1K | 0.00% | +16,811+3,296.3% | Added |
| Virtu Financial LLC | 32,570 | $38.0K | 0.01% | +32,570 | New |
| Qube Research & Technologies Ltd | 47,400 | $55.0K | 0.00% | +47,400 | New |
| Bank of New York Mellon Corp | 53,363 | $61.9K | 0.00% | +53,363 | New |
| Sabby Management, LLC | 264,000 | $306.2K | 0.82% | +264,000 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −35,865−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −14,342−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −14,159−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,425−100.0% | Sold out |